TrialCancer immunology, immunotherapy : CII2023

Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).

Yuankai Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.